Today at Diabetes UK, ABCD is pleased to announce the full launch of the nationwide semaglutide audit. As you will know, the clinical trials with semaglutide suggest that it is more effective than the other GLP-1 receptor agonists that we have to date, and it is now of interest for us to find out to what extent the experience in clinical trials translates into the real world.
In our previous audits of GLP-1 receptor agonists we have found that much heavier, more poorly controlled patients were treated than in the clinical trials and the impact of the GLP-1 receptor agonist was greater than in the clinical trials when they were used in the real world. It would be particularly interesting to see if the same applies to Semaglutide.
For more information on the justification for the audit and the things we might find out see:
To register for the audit use this link:
You will be given access to the online tool. As we have done with previous audits all contributors will be acknowledged in all papers and presentations from the audit data and biggest contributors will be offered the possibility of being co-authors.
The tool will allow you to analyse the data of your own patients for your own local interest; at the same time the data will automatically be available for national analysis of anonymised data.
Dr Bob Ryder MD. FRCP.
Clinical lead, ABCD audits of new diabetes therapies and devices
Birmingham B18 7QH